L ipoprotein(a) (Lp(a)) is a recognized risk factor for coronary heart disease (CHD).
L ipoprotein(a) (Lp(a)) is a recognized risk factor for coronary heart disease (CHD). 1 Population studies and metaanalyses show association between Lp(a) levels and first-ever CHD events, but there is less evidence in patients with overt CHD and stable clinical symptoms. In a general population cohort (Copenhagen City Heart Study), the hazard ratio (HR) for future CHD reached a significant value of 1.9 between the 67th and 89th percentiles of Lp(a) concentration. 2 Furthermore, as reported by Kamstrup et al, 3, 4 risk rises most in those patients whose Lp(a) concentration is in the top decile. Causality was predicated on the basis of a strong genetic influence on the Lp(a) level through the kringle IV type 2 size polymorphism which had been shown also to associate with future myocardial infarction. 2, 4 In a meta-analysis of 36 prospective studies that yielded 9318 cases of nonfatal myocardial infarctions and CHD deaths, the risk ratio became significant above Lp(a) levels of ≈50 mg/dL. 5 For the 22 076 first-ever fatal or nonfatal cardiovascular disease (CVD) outcomes, the association with Lp(a) was broadly continuous but modest. 6 These findings were consistent with preceding reports based on fewer studies that showed an average 1.7-fold increased risk for ischemic heart disease between the upper and lower thirds of the Lp(a) distribution. A recent very large 20-year prospective cohort study of 3467 blacks and 9851 whites showed a graded risk between Lp(a) concentration and incident CVD events which was significant only when the highest and lowest quintiles were compared with respective HRs of 1.35 and 1.27 for the 2 populations. 7 The importance of Lp(a) size polymorphisms had been appreciated for some time and summarized in a review of 36 studies that showed a doubling in CHD risk in the presence of the smaller rather than the larger isoforms (risk ratio of 2.08 for the smaller isoforms). 8 By contrast, isoform size was not a predictor of future CHD events in a 12.3-year prospective study of the Framingham Offspring Cohort, although elevated Lp(a) levels were found to have independent significant associations with CHD in men but not in women. 9 The argument for inclusion of Lp(a) concentration within a global risk profile assessment was further supported by the findings in the Prospective Cardiovascular Mủnchen prospective cohort study in which Lp(a) levels >20 mg/dL were associated with a 2.7-fold greater risk of CHD events compared with lower levels, although this was predominantly in men who also suffered from other forms of dyslipidemia and hypertension. 10 Lp(a) concentrations also associate significantly with the severity of coronary atherosclerosis. In a coronary angiographic study among 2769 patients being treated with statins, elevated Lp(a) defined as >30 mg/dL was associated with a 2.3-fold greater likelihood of significant stenosis and a 1.5-fold greater rate of major CVD events, particularly revascularizations.
11 A consensus paper issued by the European Atherosclerosis Society in 2010 12 describes Lp(a) as a causal risk factor for CHD and CVD, recommending screening for Lp(a) in people judged to be at intermediate or high risk for future CVD/CHD and treating to levels <50 mg/dL.
Thus, Lp(a) appears to be an independent risk factor in both primary and secondary settings, although much of the evidence derives from cohorts who were initially apparently free of overt CVD. There is a paucity of information on the predictive value of Lp(a) in patients with stable CVD. We report here the relationships between Lp(a) concentrations and further CHD and CVD events in patients who entered a trial of statin therapy after suffering a myocardial infarction or an admission with unstable angina, the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study.
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Materials and Methods
Materials and Methods are available in the online-only Supplement. Table 1 shows the characteristics of the 7863 patients by categories of Lp(a) at baseline. The median concentration of Lp(a) at baseline was 13.9 (25th-75th percentiles, 6.6-44.05) mg/dL with the upper decile >73.7 mg/dL; none had values >90 mg/dL. Half the patients had values <13.9 mg/dL, which are considered normal. Baseline risk factors by Lp(a) categories demonstrate significant differences according to Lp(a). The proportion of obese and diabetic subjects diminished at higher levels as did the median plasma triglyceride concentration (P<0.001 for all), total and low-density lipoprotein cholesterol levels were both higher, but Lp(a) itself would have contributed to the cholesterol content of low-density lipoprotein cholesterol. 3 Patients whose qualifying event for the study was not a previous myocardial infarction but hospitalization for unstable angina were distributed significantly more frequently in the higher Lp(a) levels as were patients with a computed lower total risk score, the components of which we have published previously. 14 Table 2 shows that Lp(a) concentrations did not differ between patients allocated placebo or pravastatin either at baseline or at 1 year (13.4 and 14.3 mg/dL; P=0.11 and 12.9 and 13.4 mg/dL; P=0.40 for placebo and pravastatin groups, respectively). On average, Lp(a) concentrations did not change significantly at 1 year with an overall median change of −0.3 (interquartile range from −2.4 to 1.0) mg/dL.
Results
The possible prognostic values of baseline Lp(a) levels and of the changes in Lp(a) from baseline to 1 year are shown in Tables 3 and 4 , respectively. Baseline Lp(a) concentrations have been analyzed to include the following: (1) the lowest 2 quartiles combined; (2) the third quartile; (3) the 75th to 90th percentiles; and (4) the upper decile. Lp(a) concentration at baseline was weakly associated with the prespecified primary outcome of CHD death or nonfatal myocardial infarction (Table 3 ; P=0.03). It was not associated with nonhemorrhagic stroke (data not shown). However, several prespecified secondary outcomes including total CHD events (P<0.001), total CVD events (P=0.002), and coronary revascularization (P<0.001) were significantly associated with baseline Lp(a) concentrations ( Table 3) .
The change in Lp(a) concentration to 1 year was of highly significant prognostic value in the Landmark model (P=0.002 for both future total CHD and total CVD outcomes; Table 4 ), although the association with stroke alone was not significant. This effect resulted in patients in the top quartile of change (whose Lp(a) increased by ≥3.4 mg/dL) experiencing total CVD events at a 23% higher rate than those in the lowest quartile (whose Lp(a) decreased by ≥2.4 mg/dL; HR, 1.23; 95% confidence interval, 1.07-1.39; P=0.002). For total CHD events, the effects were similar (HR, 1.22; 95% confidence interval, 1.08-0.41; P<0.0001). An increase in Lp(a) from baseline to year 1 was also associated with a modest increase in the HR for CVD death (HR, 1.33; 95% confidence interval, 1.02-1.74; P trend=0.04).
Two issues that may have modified the results relating to change in Lp(a) concentration during the first year were analytic variation in the 2 measurements and the possible effect of change in low-density lipoprotein cholesterol. The methodology to address those issues has been described under Materials and Methods in the online-only Data Supplement. The data shown in landmark analysis (Table 4 ) have been reanalyzed accounting for both issues. A relative change >13% from baseline is larger than can be accounted for by analytic variation. Adjusting for both issues, the levels of significance for the 2 key secondary outcomes were attenuated only marginally. For total CVD events, across the categories, decrease by >13%, remaining within 13% of the baseline, and increasing by >13%, the HR for those showing >13% increase was 1.21 (1.06-1.39; P=0.005) relative to those whose Lp(a) decreased by >13% below their baseline level. For total CHD events, the corresponding HR was 1.21 (1.05-1.39; P=0.009).
Whether the above findings might have added to the predictive value of Lp(a) concentration on future cardiovascular events was examined by C statistic analysis and classificationfree net reclassification index. The C statistic was unaltered by the addition of Lp(a), but net reclassification index ranged from 2% to 11% for the outcomes listed in Table 1 .
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Pravastatin treatment remained highly significant in its effect on the prespecified outcomes (P<0.03; Tables 3 and  4) , and there was no interaction between baseline Lp(a) and pravastatin treatment in their effects on cardiovascular outcomes. Similarly, there was no significant interaction between Lp(a) level and sex on outcomes.
Lp(a) concentration did not correlate with any of the parameters including apolipoprotein B at baseline, but change in Lp(a) correlated weakly with changes in hsC-reactive protein (r=0.09) and somewhat more strongly with changes in high-density lipoprotein cholesterol (r=0.09), low-density lipoprotein cholesterol (r=0.23), total cholesterol (r=0.14), triglycerides (r=−0.17), and apolipoprotein B (r=0.15) but not with creatinine or estimated glomerular filtration rate (r=0.00 for both), but all correlations were weak.
Discussion
In contrast to the relatively consistent predictive strength of baseline Lp(a) concentration on future cardiovascular events in subjects without overt CHD, our findings in subjects with stable CHD also demonstrate a significant effect on a composite of multiple cardiovascular outcomes. Several meta-analyses 
Triglyceride, mmol/L, median (IQR) of large numbers of prospective and case-control studies do include both primary and secondary outcome studies, although the former predominate. [2] [3] [4] [5] Our study, therefore, supports the likelihood that Lp(a) represents a significant risk factor for recurrent events. Furthermore, the findings were attributable particularly to effects in those with substantially higher Lp(a) values, namely the highest decile (>73 mg/dL). This is consistent with recent suggestions that an Lp(a) level of >50 mg/ dL should be considered a robust cutoff value at which the risk for CVD events particularly increases. 12 On the contrary, a recent study demonstrated a graded response extending into lower concentrations of Lp(a). 7 Other large prospective studies, such as the recently reported Women's Health Study, suggest a nongraded association with clear adverse cardiovascular outcomes becoming evident in the highest quintile HRs and 95% CIs are adjusted for baseline variables: treatment, sex, stroke, diabetes mellitus, smoking, hypertension, total cholesterol, apolipoprotein B, apolipoprotein A1, HDL-c, age, nature of prior acute coronary syndrome, timing of coronary revascularization, systolic blood pressure, atrial fibrillation, estimated glomerular filtration rate, body mass index, dyspnea class, angina grade, white blood cell count, peripheral vascular disease, triglycerides, fasting glucose, and aspirin use at baseline. CHD indicates coronary heart disease; CI, confidence interval; CVD, cardiovascular disease; HR, hazard ratio; Lp(a), lipoprotein(a); and MI, myocardial infarction.
*CHD events comprise nonfatal MI and CHD death. †Total CVD events comprise CVD death, nonfatal MI, nonhemorrhagic stroke, unstable angina, and coronary revascularization. ‡Total CHD events comprise major CHD events, unstable angina, and coronary revascularization. of Lp(a) concentration (>44 mg/dL). 15 However, the recently published meta-analysis by Di Angelantonio et al 16 of 37 prospective cohort studies followed for a median of 10.4 years suggested that the Lp(a) concentration did not significantly improve net risk reclassification when added to conventional risk factors. In our study, the net reclassification index showed modest improvements in some CVD outcomes. Lp(a) levels also predict severity of coronary atherosclerosis in clinically symptomatic patients. 11 Both the baseline concentration of Lp(a) and the change in Lp(a) levels in the first year showed highly significant associations for events that occurred after the first year with 2 secondary end points, total CHD events and total CVD events (Tables 3 and 4) . Furthermore, we did not observe important attenuation in the levels of significance for the effects of Lp(a) change after adjusting for possible confounding by analytic variation in Lp(a) measurements and for changes in lowdensity lipoprotein cholesterol. An effect of statin therapy can be largely excluded because pravastatin did not affect Lp(a) level ( Table 2 ). The risk of the outcomes occurring was greater when Lp(a) levels increased >13% and was lower when Lp(a) levels declined by >13% during the first year. Although Lp(a) levels are regarded as fluctuating little over time at least on average, individual subjects may show either increments or decrements, and this study demonstrated that a rising Lp(a) level is associated with cardiovascular events. HRs and 95% CIs are adjusted for baseline Lp(a) and variables: treatment, sex, stroke, diabetes mellitus, smoking, hypertension, total cholesterol, apolipoprotein B, apolipoprotein A1, HDL-c, age, nature of prior acute coronary syndrome, timing of coronary revascularization, systolic blood pressure, atrial fibrillation, estimated glomerular filtration rate, body mass index, dyspnea class, angina grade, white blood cell count, peripheral vascular disease, triglycerides, fasting glucose, and aspirin use at baseline. CHD indicates coronary heart disease; CI, confidence interval; CVD, cardiovascular disease; HR, hazard ratio; Lp(a), lipoprotein(a); and MI, myocardial infarction.
*CHD events comprise nonfatal MI and CHD death. †Total CVD events comprise CVD death, nonfatal MI, nonhemorrhagic stroke, unstable angina, and coronary revascularization. ‡Total CHD events comprise major CHD events, unstable angina, and coronary revascularization.
Consequently, there was not a consistent picture favoring Lp(a) being associated with particular component outcomes. Rather it appears that Lp(a) (baseline and change) are moderately associated with a range of CVD outcomes with greater strength of association because more events are included.
Renal function did not deteriorate over this time. Change in Lp(a) correlated with change in lipids and lipoproteins, rather than creatinine or estimated glomerular filtration rate. The baseline Lp(a) concentration was inversely related to plasma triglyceride concentration and type 2 diabetes mellitus prevalence, as has been reported by others. 17 This inverse association between Lp(a) concentration and type 2 diabetes mellitus (Table 1) appears paradoxical but confirms similar observations in the Women's Health Study 15 and the Copenhagen Heart Study. 18 The LIPID cohort is one of the best characterized trials in CHD with ascertainment of vital status in all but 1 patient and adjudication of major cardiovascular events, the end points in the present study, in all. The 7863 patients in whom adequate plasmas were stored under optimal conditions and available for a comprehensive biomarker investigation, including Lp(a), did not reflect loss to follow-up from the initial 9014-patient cohort. The reduced number reflected patients who had died or in whom samples of plasma were insufficient for the full range of assays.
Mechanisms that may account for the association of Lp(a) with CVD outcomes must be speculative in the absence of certainty about its functions. Potential antithrombolytic activity has been proposed because of structural similarity with plasminogen the activity of which Lp(a) may oppose. 19 A recent editorial supported its role as a prothrombotic factor by pointing out that Lp(a) appears to be significantly associated with carotid artery occlusion but not plaque size. 20 On the contrary, there may be a stronger linkage between the kringle IV type 2 genotype and atherosclerotic stenosis in large arteries than with thrombosis in veins. 21 Further support for a stronger link to atherosclerosis than to thrombosis was reported from the Trial of Org 10172 in Acute Stroke, 22 which investigated the association of 2 variations in the LPA gene with subtypes of acute stroke. LPA score from the 2 variants combined was significantly associated with large artery atherosclerosis ischemic stroke, peripheral artery disease, extent of coronary atherosclerosis, and abdominal aneurysm, but not with stroke caused by emboli or small vessel disease or with venous thrombosis. The 2 variants in the LPA gene have been shown to associate with higher Lp(a) concentrations, which in turn increase the risk of CVD. 23 The consistent observations from the laboratory of Tsimikas and Witztum 24 of a strong correlation between the circulating levels of Lp(a) and oxidized phospholipid/apolipoprotein B complex which were together directly associated with CVD outcomes suggested to them that Lp(a) transported the proinflammatory burden of oxidized phospholipids. These findings that were attributed to possible increased efflux from plaques of the oxidized lipoprotein complex were demonstrated in prospective cohort studies and were associated with angiographic coronary artery disease. 25 Elevated Lp(a) levels may augment the CHD risk from increased low-density lipoprotein cholesterol concentrations as has been demonstrated in patients with familial hypercholesterolemia. 26 Experimental studies have shown that Lp(a) may contribute to foam cell formation. 27 The possibility that Lp(a) may become functionally altered in patients with coronary artery disease has been put forward by Tsironis et al 28 on the basis of mass and specific activity of Lp(a) as mediator of platelet-activating factor acetylhydrolase activity, an enzyme that hydrolyzes oxidized phospholipids. Additional proatherogenic properties of elevated Lp(a) concentrations have been reported as summarized in a recent editorial. 29 In addition, recent evidence suggests that genetic variation in the LPA locus mediated by Lp(a) concentration may also predict aortic valve stenosis. 30 An emerging clinical challenge to define the role of Lp(a) in CVD lies in the possibility of lowering the concentration of Lp(a) by therapies other than nicotinic acid, which may be effective, as with antisense oligonucleotides, as an inhibitor of proprotein convertase subtilisin/kexin type 9 31 and cholesterol ester transfer protein inhibition. 32 Limitations of this study include lengthy storage, which has been shown to reduce Lp(a) values modestly 33 but would have reduced rather than increased the calculated risk. Our assay did not define the isoform pattern which bears on cardiovascular outcomes. One limitation of this current study is, therefore, the absence of Lp(a) isoform data, which may have improved the significance of an association with CHD outcomes. Most studies, with the notable exception of the Framingham Offspring Study, 9 indicate a significantly greater association with smaller than larger isoforms.
The coefficient of variation resembled that in other studies but we cannot exclude that greater precision may have led to different degrees of significance, although the large cohort and the high levels of statistical significance support the validity of our conclusions.
In conclusion, our current study confirms a significant association between Lp(a) concentration and future cardiovascular events in patients with stable ischemic heart disease. Those associations were highly significant in a model that analyzed events among patients with substantially elevated Lp(a) values at baseline, especially those in the top decile of the distribution. A further finding was that among patients whose Lp(a) concentration increased 1 year after randomization into the study, total CHD events and total CVD events increased significantly during the following 5 years.
That period spanned the randomized part of the study and included both pravastatin-and placebo-treated groups. The prognostic value of Lp(a) at baseline and that related to change at 1 year was attributable to the concentrations in the upper decile and quartile, respectively. The recent reassessment of Lp(a) as an important CVD risk factor is supported by this study.
